We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Oncologic Panel Meeting to Focus On Postmarketing Commitments
Oncologic Panel Meeting to Focus On Postmarketing Commitments
October 14, 2005
The FDA will call on its Oncologic Drugs Advisory Committee next month to provide recommendations on how drugmakers can better meet postmarketing commitments for drugs cleared under the accelerated approval process.